Introduction: Glial tumours are primary tumours of the central nervous system. They may be localised or diffuse. Diffuse gliomas are the most common primary tumours of the central nervous system encountered in neuro-oncological practice. The 5th edition (2021) of the WHO classification of tumours of the central nervous system requires that the morphological diagnosis be supplemented by the identification of molecular alterations using immunohistochemistry and molecular biology techniques. These techniques are still struggling to be implemented in resource-limited settings such as those in Burkina Faso. We initiated this study with the dual aim of establishing the histo-epidemiological profile of gliomas diagnosed in Burkina Faso between 2014 and 2023 according to the 2007 WHO classification, and of reporting the molecular alterations associated with diffuse gliomas using immunohistochemical techniques in line with modern criteria. Methodology: We conducted a cross-sectional, descriptive, and analytical study involving retrospective data collection, including all cases of histologically confirmed gliomas from all pathological anatomy laboratories in Burkina Faso between 1 January 2014 and 31 December 2023. For each case, we collated the available sociodemographic, clinical, radiological, and pathological data. An immunohistochemical re-evaluation was then carried out on diffuse gliomas using formalin-fixed, paraffin-embedded (FFPE) tissue blocks. The panel of antibodies used included antibodies against: GFAP, IDH1-R132H, p53, ATRX, Olig2, INA, and Ki-67. Results: Over a ten-year period, we collected data on 463 CNS tumours, of which 154 were gliomas, representing 33.33%. The average annual incidence of gliomas was 15.4 new cases. The sex ratio was 1.75. The mean age of patients was 32.7 years, with a median of 30 years and a range of 1 to 80 years. Standard histological examination revealed 62.99% astrocytic tumours, 26.62% glioblastomas, and 9.09% oligodendrogliomas. Immunohistochemical analysis of 33 cases identified an IDH mutation in 78.8% of cases and yielded the following profiles: 1) Seven low-grade astrocytomas (grade 2) with IDH mutation. 2) Four anaplastic astrocytomas (grade 3) with an IDH mutation. 3) Five gliomas without an IDH mutation (IDH wild-type), requiring further investigation. 4) Five cases suggestive of oligodendroglioma (requiring confirmation by testing for 1p/19q co-deletion). 5) Most notably, 12 cases initially classified as “IDH-mutated glioblastomas” were reclassified as “grade 4
References
[1]
Martin-Duverneuil, N. and Mokhtari, K. (2009) Les tumeurs intracraniennes de l’adulte. Sauramps Medical.
[2]
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. https://doi.org/10.3322/caac.21834
[3]
Al-Fikri, A.A.B., Alhammadi, M., Arum, C., Kaur, M., Del Biondo, K., Bani, I., et al. (2025) Primary Tumors of the Brain and Central Nervous System in Adults and Children in Sub-Saharan Africa: Protocol for a Scoping Review. JMIR Research Protocols, 14, e66978. https://doi.org/10.2196/66978
[4]
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., et al. (2013) An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science, 340, 626-630. https://doi.org/10.1126/science.1236062
[5]
Chen, J., Yao, Y., Xu, H. and Qin, Z. (2016) Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients with Glioblastomas. Medicine, 95, e2583. https://doi.org/10.1097/md.0000000000002583
[6]
Soffietti, R., Franchino, F., Magistrello, M., Pellerino, A. and Rudà, R. (2018) Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. In: Muragaki, Y., Kesari, S., McCutcheon, I.E. and Chernov, M.F., Eds., Progress in Neurological Surgery, S. Karger AG, 168-179. https://doi.org/10.1159/000467378
[7]
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., et al. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathologica, 131, 803-820. https://doi.org/10.1007/s00401-016-1545-1
[8]
Figarella-Branger, D., Appay, R., Metais, A., Tauziède-Espariat, A., Colin, C., Rousseau, A., et al. (2022) La classification de l’OMS 2021 des tumeurs du système nerveux central. Annales de Pathologie, 42, 367-382. https://doi.org/10.1016/j.annpat.2021.11.005
[9]
Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., et al. (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro-Oncology, 23, 1231-1251. https://doi.org/10.1093/neuonc/noab106
[10]
Appin, C.L. and Brat, D.J. (2015) Biomarker-Driven Diagnosis of Diffuse Gliomas. Molecular Aspects of Medicine, 45, 87-96. https://doi.org/10.1016/j.mam.2015.05.002
[11]
Louis, D.N., Perry, A., Burger, P., Ellison, D.W., Reifenberger, G., von Deimling, A., et al. (2014) International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. Brain Pathology, 24, 429-435. https://doi.org/10.1111/bpa.12171
[12]
Neff, C., Cioffi, G., Waite, K., Kruchko, C., Barnholtz-Sloan, J.S., Ostrom, Q.T., et al. (2023) Molecular Marker Testing and Reporting Completeness for Adult-Type Diffuse Gliomas in the United States. Neuro-Oncology Practice, 10, 24-33. https://doi.org/10.1093/nop/npac079
[13]
Kros, J.M., Gorlia, T., Kouwenhoven, M.C., Zheng, P., Collins, V.P., Figarella-Branger, D., et al. (2007) Panel Review of Anaplastic Oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations with Outcome. Journal of Neuropathology and Experimental Neurology, 66, 545-551. https://doi.org/10.1097/01.jnen.0000263869.84188.72
[14]
Zabsonre, D.S., Dabilgou, A.A., Dao, A., et al. (2016) Aspects épidemiologiques et évolutifs des tumeurs cérébrales au Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou. Burkina Médical, 20, 25-32.
[15]
Zongo, N., Ouedraogo, S., Sanon-Lompo, S., et al. (2021) Incidences et Evolution des Frequences des Cancers au Burkina Faso de 1988 a 2018. Burkina Médical, 25, 81-95.
[16]
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
[17]
Ostrom, Q.T., Price, M., Neff, C., Cioffi, G., Waite, K.A., Kruchko, C., et al. (2022) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro-Oncology, 24, v1-v95. https://doi.org/10.1093/neuonc/noac202
[18]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[19]
Eyenga, V., Ngah, J.E., Atangana, R., Etom, E., Ngowe, M.N., Bassong, Y., et al. (2008) Les tumeurs du système nerveux central au Cameroun: Histopathologie, démographie. Cahiers de Santé, 18, 039-042. https://doi.org/10.1684/san.2008.0096
[20]
Lukuaku, B.R., Kouandzi, P.D.M., Bumwana, A.F., et al. (2025) Clinicopathological and Epidemiological Profile of Brain Tumors in Kinshasa, DRC. Health Research in Africa, 3, 80-84.
[21]
Defossez, G., Le Guyader-Peyrou, S., Uhry, Z., et al. (2019) Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Santé Publique France.
[22]
Kruchko, C., Ostrom, Q.T., Gittleman, H. and Barnholtz-Sloan, J.S. (2018) The CBTRUS Story: Providing Accurate Population-Based Statistics on Brain and Other Central Nervous System Tumors for Everyone. Neuro-Oncology, 20, 295-298. https://doi.org/10.1093/neuonc/noy006
[23]
Figarella-Branger, D., Chappe, C., Padovani, L., Mercurio, S., Colin, C., Forest, F., et al. (2013) Les tumeurs gliales et glioneuronales de l’adulte et de l’enfant: Principales altérations génétiques et classification histomoléculaire. Bulletin du Cancer, 100, 715-726. https://doi.org/10.1684/bdc.2013.1789
[24]
Zouaoui, S., Rigau, V., Mathieu-Daudé, H., Darlix, A., Bessaoud, F., Fabbro-Peray, P., et al. (2012) Recensement national histologique des tumeurs primitives du système nerveux central: Résultats généraux sur 40 000 cas, principales applications actuelles et perspectives. Neurochirurgie, 58, 4-13. https://doi.org/10.1016/j.neuchi.2012.01.004
[25]
Koda, M., Abe, T., Funayama, T., Noguchi, H., Miura, K., Nagashima, K., et al. (2018) Postoperative Recovery Course, but Not Preoperative Factors and Operative Kyphosis Correction Can Predict Final Neurological Outcome of Posterior Decompression with Instrumented Surgery for Ossification of the Posterior Longitudinal Ligament of the Thoracic Spine. Journal of Clinical Neuroscience, 53, 85-88. https://doi.org/10.1016/j.jocn.2018.04.032
[26]
Andrews, N., Ramesh, R. and Odjidja, T. (2004) A Preliminary Survey of Central Nervous System Tumors in Tema, Ghana. West African Journal of Medicine, 22, 167-172. https://doi.org/10.4314/wajm.v22i2.27942
[27]
Rossi, S., Baili, P., Capocaccia, R., Caldora, M., Carrani, E., Minicozzi, P., et al. (2015) The EUROCARE-5 Study on Cancer Survival in Europe 1999-2007: Database, Quality Checks and Statistical Analysis Methods. European Journal of Cancer, 51, 2104-2119. https://doi.org/10.1016/j.ejca.2015.08.001
[28]
Touati, S., Djekkoun, R., El-Hadef El-Okki, M. and Satta, D. (2020) Epidemiology and Survival Analyses of 333 Adult Glioma Patients from Eastern Algeria (2008-2016). African Health Sciences, 20, 1250-1258. https://doi.org/10.4314/ahs.v20i3.29
[29]
Singh, S., Deora, H., Neyaz, A., Das, K.K., Mehrotra, A., Srivastava, A.K., et al. (2021) Trends in Clinico-Epidemiology Profile of Surgically Operated Glioma Patients in a Tertiary Care Center over 12 Years—Through the Looking Glass! Egyptian Journal of Neurosurgery, 36, Article No. 32. https://doi.org/10.1186/s41984-021-00118-w
[30]
De Angelis, R., Sant, M., Coleman, M.P., Francisci, S., Baili, P., Pierannunzio, D., et al. (2014) Cancer Survival in Europe 1999-2007 by Country and Age: Results of Eurocare-5—A Population-Based Study. The Lancet Oncology, 15, 23-34. https://doi.org/10.1016/s1470-2045(13)70546-1
[31]
Nyalundja, A.D., Kanmounye, U.S., Karekezi, C., Laeke, T., Thango, N. and Balogun, J.A. (2024) Pediatric Brain Tumors in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Journal of Neurosurgery: Pediatrics, 33, 524-535. https://doi.org/10.3171/2024.1.peds23282
